<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">686561</article-id><article-id pub-id-type="doi">10.26442/00403660.2025.09.203346</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Reviews</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Обзоры</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Cardiovascular-kidney-metabolic syndrome: the interdisciplinary approach. A review</article-title><trans-title-group xml:lang="ru"><trans-title>Кардио-рено-метаболический синдром: междисциплинарный подход</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5820-1759</contrib-id><name-alternatives><name xml:lang="en"><surname>Trushina</surname><given-names>Olga Iu.</given-names></name><name xml:lang="ru"><surname>Трушина</surname><given-names>Ольга Юрьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д-р мед. наук, проф. каф. факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского</p></bio><email>mironova_o_yu@staff.sechenov.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-10-20" publication-format="electronic"><day>20</day><month>10</month><year>2025</year></pub-date><volume>97</volume><issue>9</issue><issue-title xml:lang="en">Issues of cardiology</issue-title><issue-title xml:lang="ru">Вопросы кардиологии</issue-title><fpage>789</fpage><lpage>792</lpage><history><date date-type="received" iso-8601-date="2025-07-02"><day>02</day><month>07</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-07-02"><day>02</day><month>07</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/686561">https://ter-arkhiv.ru/0040-3660/article/view/686561</self-uri><abstract xml:lang="en"><p>The revealed interrelationships between obesity, type 2 diabetes mellitus, cardiovascular diseases and chronic kidney disease are an important problem of modern healthcare worldwide, which is gradually becoming an epidemic. The study of these diseases in such a combination becomes the subject of discussion among scientists and the topic of various consensus documents. Factors such as hyperglycemia, insulin resistance, increased activity of the renin-angiotensin-aldosterone system, formation of glycation end products, oxidative stress, calcium metabolism disorders, mitochondrial malfunctions, and persistent chronic inflammation are fundamental to understanding of this syndrome (or disorder) and developing approaches to prevention and treatment. This review article describes both the basic principles of diagnosis and treatment of cardio renal metabolic syndrome and approaches to primary and secondary prevention.</p></abstract><trans-abstract xml:lang="ru"><p>Выявленные взаимосвязи между ожирением, сахарным диабетом 2-го типа, сердечно-сосудистыми заболеваниями и хронической болезнью почек, постепенно приобретающими характер эпидемии, являются важной проблемой современного здравоохранения во всем мире. Изучение этих заболеваний именно в таком сочетании становится предметом обсуждения ученых и темой различных консенсусных документов. Такие факторы, как гипергликемия, инсулинорезистентность, повышенная активность ренин-ангиотензин-альдостероновой системы, образование конечных продуктов гликирования, окислительный стресс, нарушения в метаболизме кальция, сбои в работе митохондрий и стойкое хроническое воспаление, являются основополагающими для понимания данного состояния и разработки подходов к профилактике и лечению. В обзорной статье дается характеристика как основных принципов диагностики и лечения кардио-рено-метаболического синдрома, так и подходов к первичной и вторичной профилактике.</p></trans-abstract><kwd-group xml:lang="en"><kwd>cardiovascular-kidney-metabolic syndrome</kwd><kwd>cardiorenal syndrome</kwd><kwd>CaReMe risk factors</kwd><kwd>cardiovascular-kidney-metabolic syndrome</kwd><kwd>obesity</kwd><kwd>chronic kidney disease</kwd><kwd>metabolic syndrome</kwd><kwd>chronic cardiovascular-kidney disorder</kwd><kwd>prognosis</kwd><kwd>diabetes</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>сердечно-сосудисто-почечно-метаболический синдром</kwd><kwd>кардиоренальный синдром</kwd><kwd>КаРеМе факторы риска</kwd><kwd>кардио-рено-метаболический синдром</kwd><kwd>ожирение</kwd><kwd>хроническая болезнь почек</kwd><kwd>метаболический синдром</kwd><kwd>хроническое сердечно-сосудисто-почечное нарушение</kwd><kwd>прогноз</kwd><kwd>сахарный диабет</kwd></kwd-group><funding-group><funding-statement xml:lang="en">This study was supported by Bayer company. During the preparation of the manuscript, the author maintained the independence of opinion.</funding-statement><funding-statement xml:lang="ru">Материал подготовлен при финансовой поддержке компании «Байер». При подготовке рукописи автор сохранил независимость мнений.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Tsao CW, Aday AW, Almarzooq ZI, et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2023 Update: A Report from the American Heart Association. Circulation. 2023;147(8):e93-e621. DOI:10.1161/CIR.0000000000001123</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Salam AM, Carr AS. From “Heart and Reins” to Clinical Syndromes: Origin and Evolution of Cardio-Renal Disease. Heart Views. 2021;22:80-4. DOI:10.4103/HEARTVIEWS.HEARTVIEWS_210_20</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Braunwald E. From cardiorenal to cardiovascular-kidney-metabolic syndromes. Eur Heart J. 2025;46(8):682-4. DOI:10.1093/eurheartj/ehae775</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Bright R. Cases and Observations, Illustrative of Renal Disease Accompanied with the Secretion of Albuminous Urine. Guy’s Hosp Rep. 1836;1:338-79.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Lewis T. A clinical lecture on paroxysmal dyspnoea in cardio-renal patients: with special reference to “cardiac” and “uraemic” asthma: delivered at University College Hospital, London, November 12th, 1913. Br Med J. 1913;2(2761):1417-20. DOI:10.1136/bmj.2.2761.1417</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Heywood JT. The cardiorenal syndrome: lessons from the ADHERE database and treatment options. Heart Fail Rev. 2004;9(3):195-201. DOI:10.1007/s10741-005-6129-4</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527-39. DOI:10.1016/j.jacc.2008.07.051</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Hatamizadeh P. Introducing nephrocardiology. Clin J Am Soc Nephrol. 2022;17:311-3. DOI:10.2215/CJN.10940821</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Braunwald E. Diabetes, heart failure, and renal dysfunction: The vicious circles. Prog Cardiovasc Dis. 2019;62(4):298-302. DOI:10.1016/j.pcad.2019.07.003</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Чазова И.Е., Шестакова М.В., Жернакова Ю.В., и др. Евразийские рекомендации по профилактике и лечению сердечно-сосудистых заболеваний у больных с диабетом и предиабетом (2021). Евразийский Кардиологический Журнал. 2021;(2):6-61 [Chazova IE, Shestakova MV, Zhernakova YuV, et al. Eurasian Association of Cardiology (EAC) Guidelines for the Prevention and Treatment of Cardiovascular Diseases in Patients with Diabetes and Prediabetes (2021). Eurasian Heart Journal. 2021;(2):6-61 (in Russian)]. DOI:10.38109/2225-1685-2021-2-6-61</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Миронова О.Ю., Староверов И.И., Сивакова О.А., и др. Контраст-индуцированное острое повреждение почек у больных хронической ишемической болезнью сердца в сочетании с сахарным диабетом и ожирением. Терапевтический архив. 2020;92(10):29-33 [Mironova OIu, Staroverov II, Sivakova OA, et al. Contrast-induced acute kidney injury in chronic coronary artery disease patients with diabetes mellitus and obesity. Terapevticheskii Arkhiv (Ter. Arkh.). 2020; 92(10):29-33 (in Russian)]. DOI:10.26442/00403660.2020.10.000753</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Ndumele CE, Neeland IJ, Tuttle KR, et al. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association. Circulation 2023;148(20):1636-64. DOI:10.1161/CIR.0000000000001186</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Миронова О.Ю., Сивакова О.А., Деев А.Д., Фомин В.В. Сердечная недостаточность и контрастиндуцированное острое повреждение почек у больных с ишемической болезнью сердца. Consilium Medicum. 2020;22(10):61-3 [Mironova OI, Sivakova OA, Deev AD, Fomin VV. Heart failure and contrast-induced acute kidney injury in patients with coronary artery disease. Consilium Medicum. 2020; 22(10):61-3 (in Russian)]. DOI:10.26442/20751753.2020.10.200352</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Миронова О.Ю., Фомин В.В. Прогностическая значимость контраст-индуцированного острого повреждения почек у больных с хронической ишемической болезнью сердца. Consilium Medicum. 2020;22(5):73-6 [Mironova OI, Fomin VV. Prognostic significance of contrast-induced acute kidney injury in chronic coronary artery disease patients. Consilium Medicum. 2020;22(5):73-6 (in Russian)]. DOI:10.26442/20751753.2020.5.200218</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Ndumele CE, Rangaswami J, Chow SL, et al. American Heart Association. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory from the American Heart Association. Circulation. 2023;148(20):1606-35. DOI:10.1161/CIR.0000000000001184</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Braunwald E. Gliflozins in the Management of Cardiovascular Disease. N Engl J Med. 2022;386(21):2024-34. DOI:10.1056/NEJMra2115011</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474-84. DOI:10.1093/eurheartj/ehab777</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Vaduganathan M, Filippatos G, Claggett BL, et al. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat Med. 2024;30(12):3758-64. DOI:10.1038/s41591-024-03264-4</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Agarwal R, Fouque D. The foundation and the four pillars of treatment for cardiorenal protection in people with chronic kidney disease and type 2 diabetes. Nephrol Dial Transplant. 2023;38(2):253-7. DOI:10.1093/ndt/gfac331</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Ferdinand KC, Rodriguez F, Nasser SA, et al. Cardiorenal metabolic syndrome and cardiometabolic risks in minority populations. Cardiorenal Med. 2014;4(1):1-11. DOI:10.1159/000357236</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Kim HL, Chung J, Kim KJ, et al. Lifestyle Modification in the Management of Metabolic Syndrome: Statement From Korean Society of CardioMetabolic Syndrome (KSCMS). Korean Circ J. 2022;52(2):93-109. DOI:10.4070/kcj.2021.0328</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Lloyd-Jones DM, Liu K, Colangelo LA. Consistently stable or decreased body mass index in young adulthood and longitudinal changes in metabolic syndrome components: the Coronary Artery Risk Development in Young Adults Study. Circulation. 2007;115(8):1004-11. DOI:10.1161/ CIRCULATIONAHA.106.648642</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Carnethon MR, Loria CM, Hill JO, et al. Coronary artery risk development in young adults study. Risk factors for the metabolic syndrome: the Coronary Artery Risk Development in Young Adults (CARDIA) study, 1985–2001. Diabetes Care. 2004;27(11):2707-15. DOI:10.2337/diacare.27.11.2707</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-e646. DOI:10.1161/CIR.0000000000000678</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2014;(4):CD007004. DOI:10.1002/14651858.CD007004.pub3</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Alexandrou ME, Papagianni A, Tsapas A. Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019;37(12):2307-24. DOI:10.1097/HJH.0000000000002187</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Kolkhof P, Delbeck M, Kretschmer A, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64(1):69-78. DOI:10.1097/FJC.0000000000000091</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Gerisch M, Heinig R, Engelen A, et al. Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro. Drug Metab Dispos. 2018;46(11):1546-55. DOI:10.1124/dmd.118.083337</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383(23):2219-29. DOI:10.1056/NEJMoa2025845</mixed-citation></ref></ref-list></back></article>
